Skip to Content
Merck

Regulation of FSP27 protein stability by AMPK and HSC70.

American journal of physiology. Endocrinology and metabolism (2014-10-16)
Xiaodong Zhang, Bradlee L Heckmann, Xitao Xie, Alicia M Saarinen, Jun Liu
ABSTRACT

Fat-specific protein 27 (FSP27) plays a pivotal role in controlling the formation of large lipid droplet and energy metabolism. The cellular levels of FSP27 are tightly regulated through the proteasomal ubiquitin-mediated degradation. However, the upstream signals that trigger FSP27 degradation and the underlying mechanism(s) have yet to be identified. Here we show that AMP-activated protein kinase (AMPK) activation by AICAR (5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide) or phenformin induced the ubiquitination of FSP27 and promoted its degradation in 3T3-L1 adipocytes. The levels of FSP27 protein could be maintained by either knocking down AMPKα1 or blocking proteasomal pathway. Moreover, AICAR treatment induced multilocularization of LDs in 3T3-L1 adipocytes, reminiscent of the morphological changes in cells depleted of FSP27. Furthermore, mass spectrometry-based proteomic analysis identified heat shock cognate 70 (HSC70) as a novel binding protein of FSP27. The specific interaction was confirmed by co-immunoprecipitation of both ectopically expressed and endogenous proteins. Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR. However, silencing of the E3 ubiquitin ligase CHIP (COOH terminus of HSC70-interacting protein) failed to alter the stability of FSP27 protein under both conditions. Taken together, our data indicate that AMPK is a negative regulator of FSP27 stability through the proteasomal ubiquitin-dependent protein catabolic process. Promotion of FSP27 degradation may be an important factor responsible for the beneficial effect of AMPK activators on energy metabolism.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Amino-4-imidazolecarboxamide, 95%
Dacarbazine impurity B, European Pharmacopoeia (EP) Reference Standard
Supelco
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5′-monophosphate, analytical standard
Sigma-Aldrich
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5′-monophosphate, ≥93%